IP Library Patent Application 12890183
Patent Application
App. No. 12/890,183

METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/890,183
Abstract

Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof.

Claims (13)

1 . A method for treating mycosis fungoides comprising topically applying to the affected skin a composition comprising an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the response rate in a group of human patients is greater than about 60% after at least six months of treatment.

2 . The method of claim 1 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.015% to about 0.030% by weight of the composition.

3 . The method of claim 1 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.10% by weight of the composition.

4 . A method for treating mycosis fungoides comprising topically applying to the affected skin a composition comprising an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the response rate in a group of human patients is greater than about 55% upon two months of treatment.

5 . The method of claim 4 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.015% to about 0.030% by weight of the composition.

6 . The method of claim 4 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.10% by weight of the composition.

7 . A method for treating mycosis fungoides comprising topically applying to the affected skin a composition comprising an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the response rate in an intent-to-treat group of human patients is greater than about 50%.

8 . The method of claim 7 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.015% to about 0.030% by weight of the composition.

9 . The method of claim 7 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.10% by weight of the composition.

10 . A method for treating mycosis fungoides comprising topically applying to the affected skin a composition comprising an effective amount of bis-(2-chloroethyl)methylamine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the time to achieve a response rate of 50% in a group of human patients is about 40 weeks or less.

11 . The method of claim 10 , wherein the response rate is about 30 weeks or less.

12 . The method of claim 10 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.015% to about 0.030% by weight of the composition.

13 . The method of claim 10 , wherein the bis-(2-chloroethyl)methylamine or pharmaceutically acceptable salt thereof is present in an amount of about 0.01% to about 0.10% by weight of the composition.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CEPTARIS THERAPEUTICS, INC.
To: ACTELION PHARMACEUTICALS, LTD.
Reel/Frame 031896/0320 →
CHANGE OF NAME Recorded Feb 24, 2012
From: YAUPON THERAPEUTICS, INC.
To: CEPTARIS THERAPEUTICS, INC.
Reel/Frame 027757/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2010
From: ALONSO, ROBERT; STOGNIEW, MARTIN
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 025234/0816 →